Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gross Profit: 2013-2024

Historic Gross Profit for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to $302,000.

  • Viridian Therapeutics, Inc.\DE's Gross Profit rose 81958.14% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year increase of 23340.07%. This contributed to the annual value of $302,000 for FY2024, which is 3.82% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Gross Profit of $302,000 as of FY2024, which was down 3.82% from $314,000 recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Gross Profit peaked at $3.0 million during FY2021, and registered a low of $302,000 during FY2024.
  • Its 3-year average for Gross Profit is $796,000, with a median of $314,000 in 2023.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 182.19% in 2021, then tumbled by 82.28% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Gross Profit (Yearly) stood at $1.1 million in 2020, then soared by 182.19% to $3.0 million in 2021, then tumbled by 40.20% to $1.8 million in 2022, then plummeted by 82.28% to $314,000 in 2023, then declined by 3.82% to $302,000 in 2024.